ENCORE randomized 425 patients to ALIS+azithromycin+ethambutol versus empty-liposome control+azithromycin+ethambutol, with >90% completion and balanced baseline characteristics in newly diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results